Extramedullary relapsed multiple myeloma has extremely poor prognosis even in the era of the new drugs

Warning

This publication doesn't include Institute of Computer Science. It includes Faculty of Medicine. Official publication website can be found on muni.cz.
Authors

POUR Luděk SANDECKÁ Viera KAISAROVÁ Petra ADAM Zdeněk KREJČÍ Marta ZAHRADOVÁ Lenka KLINCOVÁ Mária SZTURZ P. ŠEVČÍKOVÁ Sabina HÁJEK Roman

Year of publication 2010
Type Conference abstract
MU Faculty or unit

Faculty of Medicine

Citation
Description Our data showed higher incidence of EM relapse in comparison with 90's .Interval of survival after EM relapse and is extremely short if EM occurs, although all new drugs including IMIDs and bortezomib are used for the treatment. Our findings indicate that EM still means very poor prognosis of MM patients even in the era of the new effective drugs, especially if ST-EM occurs. We have not yet fully understood why the incidence of EM is so high in the last 4 years. In our opinion, the treatment of EM became a crucial problem in MM, and effective treatment is unfortunately not available.
Related projects:

You are running an old browser version. We recommend updating your browser to its latest version.

More info